Lars Gedda

Publikationer

Senaste publikationer

• Dual centrifugation as a novel and efficient method for the preparation of lipodisks (2024)
• A closer look at calcium-induced interactions between phosphatidylserine-(PS) doped liposomes and the structural effects caused by inclusion of gangliosides or polyethylene glycol- (PEG) modified lipids (2024)
• Spontaneous Formation of Ultrasmall Unilamellar Vesicles in Mixtures of an Amphiphilic Drug and a Phospholipid (2023)
• Tailoring the Lamellarity of Liposomes Prepared by Dual Centrifugation (2023)
• Excited-state and charge-carrier dynamics in binary conjugated polymer dots towards efficient photocatalytic hydrogen evolution (2023)

Alla publikationer

Artiklar

• Dual centrifugation as a novel and efficient method for the preparation of lipodisks (2024)
• A closer look at calcium-induced interactions between phosphatidylserine-(PS) doped liposomes and the structural effects caused by inclusion of gangliosides or polyethylene glycol- (PEG) modified lipids (2024)
• Spontaneous Formation of Ultrasmall Unilamellar Vesicles in Mixtures of an Amphiphilic Drug and a Phospholipid (2023)
• Tailoring the Lamellarity of Liposomes Prepared by Dual Centrifugation (2023)
• Excited-state and charge-carrier dynamics in binary conjugated polymer dots towards efficient photocatalytic hydrogen evolution (2023)
• Vesicle-enriched secretomes alter bacterial competitive abilities and are drivers of evolution in microbial communities (2023)
• Polymer Dots as Photoactive Membrane Vesicles for [FeFe]-Hydrogenase Self-Assembly and Solar-Driven Hydrogen Evolution (2022)
• Influence of Chain Length of Gradient and Block Copoly(2-oxazoline)s on Self-Assembly and Drug Encapsulation (2022)
• Structural Characterization Study of a Lipid Nanocapsule Formulation Intended for Drug Delivery Applications Using Small-Angle Scattering Techniques (2022)
• Investigation of the enhanced ability of bile salt surfactants to solubilize phospholipid bilayers and form mixed micelles. (2021)
• Panchromatic Ternary Polymer Dots Involving Sub-Picosecond Energy and Charge Transfer for Efficient and Stable Photocatalytic Hydrogen Evolution (2021)
• Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery (2021)
• Effect of gangliosides on structure and integrity of polyethylene glycol(PEG)-stabilized liposomes (2020)
• Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks (2020)
• Osmoprotective effect of ubiquinone in lipid vesicles modelling the E. coli plasma membrane (2019)
• EGF-targeting lipodisks for specific delivery of poorly water-soluble anticancer agents to tumour cells (2017)
• 17AAG-induced internalisation of HER2- specific Affibody molecules (2016)
• Characterization of recombinant human bone morphogenetic protein-2 delivery from injectable hyaluronan-based hydrogels by means of I-125-radiolabelling (2014)
• Pre-incubation of chemically crosslinked hyaluronan-based hydrogels, loaded with BMP-2 and hydroxyapatite, and its effect on ectopic bone formation (2014)
• Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach (2013)
• Evaluation of Real-Time Immunohistochemistry and Interaction Map as an Alternative Objective Assessment of HER2 Expression in Human Breast Cancer Tissue (2013)
• Morphological differences in BMP-2-induced ectopic bone between solid and crushed hyaluronan hydrogel templates (2013)
• Improved bone formation by altering surface area of hyaluronan-based hydrogel carrier for bone morphogenetic protein-2 (2012)
• The HER2-binding Affibody Molecule (Z_HER2:342)₂ Increases Radiosensitivity in SKBR-3 cells (2012)
• Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2 (2012)
• Nuclisome (2012)
• Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting Nuclisome-particles (2012)
• Cellular effects of HER3-specific affibody molecules (2012)
• The importance of proper protein handling and detection for the design of a BMP-2 release system (2012)
• Avoiding false negative results in specificity analysis of protein-protein interactions (2011)
• Comparing the epidermal growth factor interaction with four different cell lines (2011)
• Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with (125)I-EGF (2011)
• In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an 125I-labelled DNA-intercalator (2011)
• Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules (2011)
• Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells (2011)
• Nuclisome (2010)
• Real-time immunohistochemistry analysis of embedded tissue (2010)
• Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF (2010)
• Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule (2009)
• Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family (2009)
• Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin (2009)
• Targeting EGFR and HER2 with 211At-labeled molecules (2008)
• Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line (2008)
• [Lu-177]pertuzumab (2007)
• In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab (2007)
• Penetration of tumor therapy interesting substances in non-vascularized metastases; Review of studies in cellular spheroids (2006)
• Penetration of tumor therapy interesting substances in non-vascularized metastases. (2006)
• Planning for intracavitary anti-EGFR radionuclide therapy of gliomas (2006)
• A novel I-125-labeled daunorubicin derivative for radionuclide-based cancer therapy (2006)
• Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours (2006)
• 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors (2006)
• Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1 (2005)
• An Aminoacridine Derivative for Radionuclide Therapy: Dna-Binding Properties Studied in a Novel Cell-Free in vitro Assay (2005)
• An aminoacridine derivative for radionuclide therapy (2005)
• EGF-receptor targeted liposomes with boronated acridine (2005)
• [(177)Lu]pertuzumab (2005)
• Radionuklidterapi - möjlig väg mot bättre behandling av cancer (2004)
• [177Lu]Bz-DTPA-EGF (2004)
• Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice (2004)
• Introductory experiments on ligand liposomes as delivery agents for boronneutron capture therapy (2003)
• Ligand liposomes and boron neutron capture therapy (2003)
• Tumor-cell targeted EGF liposomes loaded with boronated acridine (2003)
• Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF (2003)
• Cellular retention of radioactivity and increased radiation dose (2003)
• [111In]Bz-DTPA-hEGF (2003)
• Trastuzumab-conjugated boron-containing liposomes for tumor-celltargeting; development and cellular studies. (2003)
• Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents (2002)
• [111In]-DTPA-hEGF and [111In]-Bz-DTPA-hEGF (2002)
• A new antibody recognizing the vIII mutation of human epidermal growthfactor receptor. (2002)
• Internalisation and retention of EGF-dextran associated radioactivity intransfected Chinese hamster ovary cells expressing the human EGF-receptor. (2002)
• Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33 (2002)
• [111In] benzyl-DTPA-EGF, a new potential radiopeptide for targeting of glioma (2002)
• Cellular processing of iodinated and astatinated trastuzumab in cultured SK-BR-3 breast cancer cells (2002)
• Effects of dextranation on the uptake of peptides in micrometastases:studies on binding of EGF in tumor spheroids. (2001)
• The influence of lipophilicity on binding of boronated DNA-intercalatingcompounds in human glioma spheroids. (2000)
• The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma speroids (2000)
• Synthesis of [211At] N-[8-(acridin-9-ylamino)-octyl]-3- astatobenzamide, an astatinated DNA intercalator (2000)
• Cellular processing of (125)I- and (111)in-labeled epidermal growth factor(EGF) bound to cultured A431 tumor cells (2000)
• Cellular processing of ¹²⁵I- and ¹¹¹in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells (2000)
• Conjugate chemistry and cellular processing of EGF-dextran (1999)
• Closo-dodecaborate(2-) as a linker for iodination of macromolecules (1999)
• Cytotoxicity and subcellular localization of boronated phenanthridinium analogues. (1998)
• Uptake of a boronated epidermal growth factor-dextran conjugate in CHOtor expression. (1998)
• Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinicaltrials (1998)
• Epidermal growth factor-DNA conjugate for two-step targeting: development and introductory in vitro evaluation. (1997)
• Penetration and Binding of EGF-Dextran Conjugates in Cultured-Cell Spheroids (1997)
• Chemistry and biology of some low molecular weight boron compounds forboron neutron capture therapy. (1997)
• Labelling of boron containing compounds with halogen isotopes (1997)
• Development and in vitro studies of epidermal growth factor-dextranconjugates for boron neutron capture therapy. (1996)
• Two-step targeting: EGF-based conjugate for deliverance of nucleus-specific boron compounds. (1996)
• In vitro and in vivo studies of a boronated epidermal growth factor (EGF)-dextran conjugate (1996)
• Carboranyl phenanthridinium analogues: synthesis and biological evaluation. (1996)
• Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. (1994)
• Influence of liposome composition on cellular drug delivery and therapeutic effect mediated by Nuclisome-particles
• Improved bone formation through increased surface area of hyaluronan-based hydrogels when used as carriers for BMP-2
• Synthesis, radioiodination, DNA binding and cellular uptake of some doxorubicin analogues

Böcker

• Bororn neutron capture therapy. Preclinical studies of compounds for tumour targeting. (1997)

Kapitel

• The Auger effect in molecular targeting therapy. (2008)
• SLT-particles for two step targeting in boron neutron capture therapy (2001)
• Stabilised Liposomes with Double Targeting for Use in BNCT (2000)
• Boron neutron capture therapy against tumor cells with overexpression of the EGF-receptor (1996)
• Preparation of epidermal growth factor conjugates aimed for boron neutron capture therapy. (1996)
• Synthesis and initial biological evaluation of carborane-containing phenanthridinium derivatives. (1996)

Konferenser

• Preclinical research on Auger therapy (2003)
• Cellular spheroids as a micrometastasis model in preclinical tests of boron neutron capture therapy (2001)
• Stabilised liposomes with double targeting intendent for use in BNCT (2001)
• SLT-particles for two-step targeting in boron neutron capture therapy (2001)
• Two step targeting: EGF-conjugate for delivery of DNA-binding compounds. (1997)
• In vitro and in vivo studies of a boronated epidermal growth factor (EGF)-dextran conjugate. (1997)
• Carboranyl phenantridinium analogues: Synthesis and biological evaluation. (1997)